Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Methylation-Based Biomarkers for Early Detection of Urological Cancer

Volume 13, Issue 4, 2007, pp. 265-282
DOI: 10.1615/CritRevOncog.v13.i4.10
Get accessGet access

ABSTRACT

Genitourinary (prostate, bladder, and kidney) cancers together comprise the most common type of human neoplasms. As a common feature to these types of malignancy, the disease is frequently asymptomatic at its earlier stages, when curative treatment is most likely to be successful. Moreover, available tests for genitourinary cancer screening (mostly directed to prostate cancer) are characterized by variable (usually low) sensitivity and specificity, preventing a consensual support for their routine use by the medical community. Thus, the timely and accurate detection of GU cancer remains a significant clinical challenge. Over the last decade, a new generation of cancer biomarkers, based on the characterization of the methylome, has emerged and has showed promise in the detection of several common malignant tumors. The investigation of novel genitourinary cancer methylation-based markers constitutes an attractive and fast-growing research field, and several studies reported on the feasibility of examining these markers in body fluids (urine and blood) for early, noninvasive cancer detection. Importantly, the use of quantitative, high-throughput techniques enables relatively easy and reproducible detection of hypermethylation at multiple gene loci in a single test, thus facilitating its translation to the clinics. Although available data is still insufficient to support the clinical implementation of these markers at the present time, further developments in methylation analysis are likely to provide valuable tests for genitourinary cancer screening and management.

CITED BY
  1. Duarte-Pereira Sara, Paiva Filipa, Costa Vera Lúcia, Ramalho-Carvalho João, Savva-Bordalo Joana, Rodrigues Ângelo, Ribeiro Franclim Ricardo, Silva Vitor M., Oliveira Jorge, Henrique Rui, Jerónimo Carmen, Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma, European Journal of Cancer, 47, 7, 2011. Crossref

  2. Pires-Luís Ana Sílvia, Lobo Francisco, Vieira-Coimbra Márcia, Costa-Pinheiro Pedro, Antunes Luís, Oliveira Jorge, Henrique Rui, Jerónimo Carmen, MST1R methylation as a diagnostic biomarker in renal cell tumors, Acta Urológica Portuguesa, 2015. Crossref

  3. Zheng Yanan, Chen Lu, Li Jianfang, Yu Beiqin, Su Liping, Chen Xuehua, Yu Yingyan, Yan Min, Liu Bingya, Zhu Zhenggang, Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis, Clinical Biochemistry, 44, 17-18, 2011. Crossref

  4. Sánchez-Carbayo Marta, Hypermethylation in bladder cancer: biological pathways and translational applications, Tumor Biology, 33, 2, 2012. Crossref

  5. Nandagopal Lakshminarayanan, Sonpavde Guru, Circulating Biomarkers in Bladder Cancer, Bladder Cancer, 2, 4, 2016. Crossref

  6. Verdoodt B, Sommerer F, Palisaar R-J, Noldus J, Vogt M, Nambiar S, Tannapfel A, Mirmohammadsadegh A, Neid M, Inverse association of p16INK4a and p14ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer, Prostate Cancer and Prostatic Diseases, 14, 4, 2011. Crossref

  7. Costa Vera L., Henrique Rui, Danielsen Stine A., Duarte-Pereira Sara, Eknaes Mette, Skotheim Rolf I., Rodrigues Ângelo, Magalhães José S., Oliveira Jorge, Lothe Ragnhild A., Teixeira Manuel R., Jerónimo Carmen, Lind Guro E., Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples, Clinical Cancer Research, 16, 23, 2010. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain